-+ 0.00%
-+ 0.00%
-+ 0.00%
INNOVENT ANNOUNCES EXPANSION OF GLOBAL PHASE 3 MARSLIGHT-11 STUDY OF IBI363/TAK-928 (ALPHA-BIASED IL-2/PD-1 BISPECIFIC FUSION PROTEIN) IN IMMUNOTHERAPY-RESISTANT NSCLC TO INCLUDE PATIENTS WITH NON-SQUAMOUS NSCLC
Share

Please log in to view news

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending